Besides, FLT3i showed significantly increased risk of thrombocytopenia, neutropenia, anemia, skin- and cardiac-related adverse effects, increased alanine aminotransferase, and increased risk of cough and dyspnea (<i>p</i> < 0.05). The gene discussed is GPT; the disease is neutropenia.